ArticleBriefings in bioinformatics2025
Self-awareness of retrosynthesis via chemically inspired contrastive learning for reinforced molecule generation.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The recent progress of deep generative models in modeling complex real-world data distributions has enabled the generation of novel compounds with potential therapeutic applications for various diseases. However, most studies fail to optimize the properties of generated molecules from the perspective of the intrinsic nature of chemical reactions. In this work, we propose a novel molecule generation model to overcome the limitation by deep reinforcement learning, in which an agent learns to optimize the properties of molecules initialized with a chemically inspired contrastive pretrained model. We finally assess the generation model by evaluating its ability to generate inhibitors against two prominent therapeutic targets in cancer treatment. Experimental results show that our model could generate 100% valid and novel structures and also exhibits superior performance in generating molecules with fewer structural alerts against several baselines. More importantly, the molecules generated by our proposed model show potent biological activities against ataxia telangiectasia and Rad3-related (ATR) and cyclin-dependent kinase 9 (CDK9) targets in wet-lab experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.